{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:14:55Z","timestamp":1790252095650,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T00:00:00Z","timestamp":1468540800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Cukurova University Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s12032-016-0807-z","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T07:57:42Z","timestamp":1468569462000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas"],"prefix":"10.1007","volume":"33","author":[{"given":"Semra","family":"Paydas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Kilic","family":"Bagir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"Deveci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulfiliz","family":"Gonlusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,15]]},"reference":[{"key":"807_CR1","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/bjc.2014.348","volume":"111","author":"J Naidoo","year":"2014","unstructured":"Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111:2214\u20139.","journal-title":"Br J Cancer"},{"key":"807_CR2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.290.5489.84","volume":"290","author":"JV Ravetch","year":"2000","unstructured":"Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290:84\u20139.","journal-title":"Science"},{"key":"807_CR3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9316","author":"H Zheng","year":"2016","unstructured":"Zheng H, Liu X, Zhang J, Rice SJ, Wagman M, Kong Y, Zhu L, Zhu J, Joshi M, Belani CP. Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget. 2016. doi: 10.18632\/oncotarget.9316 .","journal-title":"Oncotarget"},{"key":"807_CR4","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9061","author":"L Dong","year":"2016","unstructured":"Dong L, Lv H, Li W, Song Z, Li L, Zhou S, Qui L, Qian Z, Liu X, Feng L, Meng B, Fu K, Wang X, Pan-Hammarstr\u00f6m Q, Wang P, Wang X, Zhang H. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B cell lymphoma via PD-1\/PD-L1 axis activating intracellular AKT\/m TOR pathway in tumor cells. Oncotarget. 2016. doi: 10.18632\/oncotarget.9061 .","journal-title":"Oncotarget"},{"key":"807_CR5","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8956","author":"K Chen","year":"2016","unstructured":"Chen K, Chen G, Zhang F, Zhang N, Li D, Jin J, Wu J, Ying L, Mao W, Su D. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Oncotarget. 2016. doi: 10.18632\/oncotarget.8956 .","journal-title":"Oncotarget"},{"key":"807_CR6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","volume":"141","author":"JR Webb","year":"2016","unstructured":"Webb JR, Milne K, Kroeger DR, Nelson BH. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 2016;141:293\u2013302.","journal-title":"Gynecol Oncol"},{"key":"807_CR7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00277-015-2403-2","volume":"94","author":"S Paydas","year":"2015","unstructured":"Paydas S, Ba\u011f\u0131r E, Seydaoglu G, Ercolak V, Ergin M. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Ann Hematol. 2015;94:1545\u201352.","journal-title":"Ann Hematol"},{"key":"807_CR8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11912-015-0476-7","volume":"17","author":"M Burgess","year":"2015","unstructured":"Burgess M, Gorantla V, Weis K, Tawbi H. Immunotherapy in sarcoma: future horizons. Curr Oncol Rep. 2015;17:52.","journal-title":"Curr Oncol Rep"},{"key":"807_CR9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","volume":"14","author":"WB Coley","year":"1891","unstructured":"Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg. 1891;14:199\u2013220.","journal-title":"Ann Surg"},{"issue":"8","key":"807_CR10","doi-asserted-by":"publisher","first-page":"8944","DOI":"10.18632\/oncotarget.6884","volume":"7","author":"J Zheng","year":"2016","unstructured":"Zheng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget. 2016;7(8):8944\u201355. doi: 10.18632\/oncotarget.6884 .","journal-title":"Oncotarget"},{"key":"807_CR11","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1007\/s13277-015-4622-5","volume":"37","author":"YW Koh","year":"2016","unstructured":"Koh YW, Jeon YK, Yoon DH, Suh C, Huh J. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. Tumour Biol. 2016;37:7507\u201314.","journal-title":"Tumour Biol"},{"key":"807_CR12","first-page":"11084","volume":"8","author":"L Zhang","year":"2015","unstructured":"Zhang L, Qiu M, Jin J, Li B, Wang X, Yan S, Xu R, Yang D. Programmed cell death ligand 1 (P-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int J Clin Exp Pathol. 2015;8:11084\u201391.","journal-title":"Int J Clin Exp Pathol"},{"issue":"28","key":"807_CR13","doi-asserted-by":"publisher","first-page":"26483","DOI":"10.18632\/oncotarget.4494","volume":"6","author":"MT Barrett","year":"2015","unstructured":"Barrett MT, Anderson KS, Lenkiewicz E, Andreozzi M, Cunliffe HE, Klassen CL, Dueck AC, McCullough AE, Reddy SK, Ramanathan RK, Northfelt DW, Pockaj BA. Genomic amplification of 9p24.1 targeting JAK2, PD-L1 and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget. 2015;6(28):26483\u201393. doi: 10.18632\/oncotarget.4494 .","journal-title":"Oncotarget"},{"issue":"8","key":"807_CR14","doi-asserted-by":"crossref","first-page":"e0136023","DOI":"10.1371\/journal.pone.0136023","volume":"10","author":"LH Schmidt","year":"2015","unstructured":"Schmidt LH, K\u00fcmmel A, G\u00f6rlich D, Mohr M, Br\u00f6ckling S, Mikesch JH, Gr\u00fcnewald I, Marra A, Schultheis AM, Wardelmann E, M\u00fcller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PLoS One. 2015;10(8):e0136023.","journal-title":"PLoS One"},{"issue":"6","key":"807_CR15","doi-asserted-by":"publisher","first-page":"e0131403","DOI":"10.1371\/journal.pone.0131403","volume":"10","author":"P Wu","year":"2015","unstructured":"Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One. 2015;10(6):e0131403. doi: 10.1371\/journal.pone.0131403 .","journal-title":"PLoS One"},{"key":"807_CR16","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.18632\/oncotarget.3498","volume":"6","author":"S Movva","year":"2015","unstructured":"Movva S, Wen W, Chen W, Millis SZ, Gatalica Z, Reddy S, von Mehren M, Tine BAV. Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget. 2015;6:12234\u201347.","journal-title":"Oncotarget"},{"issue":"12","key":"807_CR17","doi-asserted-by":"publisher","first-page":"e82870","DOI":"10.1371\/journal.pone.0082870","volume":"8","author":"JR Kim","year":"2013","unstructured":"Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S, Kim KM, Park HS, Lee H, Moon WS, Chung MJ, Kang MJ, Jang KY. Tumor infiltrating PD-1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8(12):e82870. doi: 10.1371\/journal.pone.0082870 .","journal-title":"PLoS One"},{"key":"807_CR18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","volume":"46","author":"SP D\u2019Angelo","year":"2015","unstructured":"D\u2019Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD, Dickson MA, Gounder M, Keohan ML, Schwartz GK, Tap WD. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46:357\u201365.","journal-title":"Hum Pathol"},{"key":"807_CR19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/2326-6066.CIR-13-0224","volume":"2","author":"JK Shen","year":"2014","unstructured":"Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2:690\u20138.","journal-title":"Cancer Immunol Res"},{"key":"807_CR20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/apm.12311","volume":"123","author":"W Zheng","year":"2014","unstructured":"Zheng W, Xiao H, Liu H, Zhou Y. Expression of programmed death 1 is correlated with progression of osteosarcoma. APMIS. 2014;123:102\u20137.","journal-title":"APMIS"},{"key":"807_CR21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrc2888","volume":"10","author":"EA Mesri","year":"2010","unstructured":"Mesri EA, Cesarman E, Boshoff C. Kaposi\u2019s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10:707\u201319.","journal-title":"Nat Rev Cancer"},{"key":"807_CR22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/bmj.319.7201.23","volume":"31","author":"B Ledergerber","year":"1999","unstructured":"Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi\u2019s sarcoma and non-Hodgkin\u2019s lymphoma with antiretroviral therapy: prospective cohort study. BMJ. 1999;31:23\u20134.","journal-title":"BMJ"},{"key":"807_CR23","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.ejca.2015.08.013","volume":"51","author":"S Kim","year":"2015","unstructured":"Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison od sarcomatous and carcinomatous areas. Eur J Cancer. 2015;51:2698\u2013707.","journal-title":"Eur J Cancer"},{"key":"807_CR24","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/JTO.0b013e318292be18","volume":"8","author":"V Velcheti","year":"2013","unstructured":"Velcheti V, Rimm DL, Schalper KA. Sarcomatoid lung carcinomas Show high levels of programmed deat ligand-1 (PD-L1). J Thorac Oncol. 2013;8:803\u20135.","journal-title":"J Thorac Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-016-0807-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-016-0807-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-016-0807-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:28:54Z","timestamp":1498314534000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-016-0807-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,15]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1007\/s12032-016-0807-z","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,15]]},"article-number":"93"}}